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WHAT IS ALREADY KNOWN ABOUT
THIS SUBJECT
• Some psychotropic medications (e.g.
benzodiazepines, sedative antidepressants,
etc.) can impair cognitive and psychomotor
functions and, therefore, endanger traffic
safety.
• There is a lack of knowledge concerning the
role in traffic safety of first and new
generations of psychotropic medications,
new and chronic users, young and old
drivers, and polypharmacy.
WHAT THIS STUDY ADDS
• There is an increased risk of having a traffic
accident after being exposed to some
psychotropic medicine classes and, in
particular, to SSRIs.
• Health care professionals and patients
should be properly informed about the
potential effects of some psychoactive
medications on driving abilities.
• The role of SSRIs in traffic safety has to be
investigated further.
AIM
To examine the association between the use of commonly prescribed
psychotropic medications and road traffic accident risk.
METHODS
A record-linkage database was used to perform a case–control study in
the Netherlands. The data came from three sources: pharmacy
prescription data, police traffic accident data and driving licence data.
Cases were defined as drivers, who had a traffic accident that required
medical assistance between 2000 and 2007. Controls were defined as
adults, who had a driving licence and had no traffic accident during the
study period. Four controls were matched for each case. The following
psychotropic medicine groups were examined: antipsychotics,
anxiolytics, hypnotics and sedatives, and antidepressants stratified in
the two groups, SSRIs and other antidepressants. Various variables, such
as age, gender, medicine half-life and alcohol use, were considered for
the analysis.
RESULTS
Three thousand nine hundred and sixty-three cases and 18 828
controls were included in the case–control analysis. A significant
association was found between traffic accident risk and exposure to
anxiolytics (OR = 1.54, 95% CI 1.11, 2.15), and SSRIs (OR = 2.03, 95% CI
1.31, 3.14). A statistically significant increased risk was also seen in
chronic anxiolytic users, females and young users (18 to 29 years old),
chronic SSRI users, females and middle-aged users (30 to 59 years old),
and intermediate half-life hypnotic users.
CONCLUSIONS
The results of this study support previous findings and confirm that
psychoactive medications can constitute a problem in traffic safety.
Both health care providers and patients should be properly informed
of the potential risks associated with the use of these medicines.
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Introduction
Impaired driving involving alcohol, illegal and legal drugs
causes, each year, a great number of traffic accidents all
over the world [1–6]. Alcohol is a recognized leading con-
tributor to road accidents and the association between
alcohol and traffic accident risk has been extensively dem-
onstrated [1–4], but, on the contrary, except for a few active
substances (e.g. benzodiazepines, sedative antidepres-
sants, opioids), the evidence of the role of medicine is still
limited [4, 5].
Epidemiological studies have shown a positive associa-
tion between psychotropic medication exposure and the
risk of having a traffic accident [1–10]. A substantial
number of studies have reported an increased traffic acci-
dent risk associated with the use of benzodiazepines [4, 5,
11–14]; however, there is still uncertainty on the traffic acci-
dent risk associated with the exposure to other psychoac-
tive medications [3–5, 11]. Owing to methodological
limitations and data availability, there is limited evidence of
the association between road accidents and some com-
monly prescribed psychotropic medications (e.g. antipsy-
chotics, antidepressants, anxiolytics, etc.), and, especially,
the role of their dose regimen, first and new generations of
medications, new and chronic users, and polypharmacy
[3–5, 7, 8, 11, 15–17].
The current pharmacoepidemiological study examined
the association between road traffic accidents and the
exposure to different psychotropic medicine classes. In
particular, it focused on the impact of factors contributing
to driving impairment (i.e. recency of the prescription,
medication half-life, gender and age) on the risk of experi-
encing a motor vehicle accident.
Methods
Data sources
We performed a case–control study, using three existing
Dutch databases (i.e. PHARMO, DVS, RDW), and focusing on
a 7 year period (2000–2007).
PHARMO is a pharmacy dispensing database which
covers a population of more than 3 million Dutch residents
[18]. In the Netherlands people commonly register with
one pharmacy and obtain all their medications from that
pharmacy so that an almost complete medication history is
available. Registration is irrespective of health insurance
and representative for the general population [19, 20].
Medicines are coded with the Anatomical Therapeutic
Chemical (ATC) classification system [21], and, among
others, the dispensing date, the prescribed dosage, the dis-
pensed quantity and the estimated duration of use are
available. PHARMO only contains de-identified informa-
tion. A unique patient identification number (PID) is
assigned to each subject who is included in this database;
the PID refers to unique patient information (e.g. date of
birth, initials, gender, etc.) that is used to perform probabi-
listic linkages [18].
The Dienst Verkeer en Scheepvaart (DVS) is the Dutch
Traffic and Navigation Authority [22]. Its database contains
data on all the traffic accidents that occurred in the Neth-
erlands and required the intervention of the police. In par-
ticular, this database stores data on drivers who were
involved in the traffic accident (e.g. initials, age, gender,
etc.) as well as traffic accident details such as the date of
accident, day of the week, weather conditions, light condi-
tions, severity of injuries incurred and breath test for
alcohol excess.
The Rijks Dienst Wegverkeer (RDW) is the Dutch Road
Transport Authority [23]. Its database contains all the avail-
able data on registered vehicles, their owners, vehicle reg-
istration numbers and driving licence numbers.
Database linkage
The database linkage was carried out by a Trusted
Third party (TTP), within the PHARMO Institute, which
granted full compliance with the current Dutch privacy
regulations.
The database linkage was carried out in two phases. In
the first phase of the linking process, the DVS database
was linked to the RDW database by following a determin-
istic linkage methodology (1:1) based on the driving
licence numbers belonging to those subjects who were
involved in a traffic accident, and, consequently, stored in
both databases. In the second phase of the linking
process, the DVS + RDW database was linked to the
PHARMO database. This phase was based on a probabi-
listic record linkage technology which is a purely statisti-
cal methodology [24]. This technology is widely used to
perform database linkages and has been described in
detail elsewhere [24, 25].
Approximately 3% of the car accidents that occurred in
the Netherlands, in the study time frame,could be included
in the database linkage process.
Inclusion and exclusion criteria
Cases were defined as adults (18 years or older), who had a
traffic accident attended by the Dutch police between 1
January 2000 and 31 December 2007. Based on the police
data, at the time of the accident, the subjects were driving,
and, after their traffic accident, medical assistance was
received and the seriousness of the accident was assessed.
Cases were restricted to those subjects who were found
negative for alcohol use.
Controls were defined as adults (18 years or older), who
had a driving licence and had no traffic accident during the
study period. Four controls were matched for each case;
the matching was by gender, age within 5 years, zip code,
and date of the accident of the correspondent case (i.e. the
control’s complete medication record had to be available
in the PHARMO database at the time the correspondent
case had an accident).
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Study medications and exposure definitions
The following psychotropic medications, known to be of rel-
evance for traffic safety, were included: antipsychotics (ATC
code: N05A), anxiolytics (ATC code: N05B), hypnotics and
sedatives (N05C), antidepressants stratified in selective sero-
tonin re-uptake inhibitors (SSRIs) and other antidepressants
[i.e.non-selective monoamine re-uptake inhibitors;monoam-
ine oxidase A inhibitors (MAOs); other antidepressants].
Anxiolytic and hypnotic benzodiazepines were strati-
fied according to their half-life (short 12 h; intermediate
>12 h and 24 h; long >24 h) [26].
Cases and controls were considered to be exposed if
the medication was used during the week before the acci-
dent date (i.e. index date) (Figure 1). The day after the dis-
pensing date was considered as the start of the therapy. If
the therapy ended 2 days before the index date, the sub-
jects were still considered as exposed (Figure 1). Medica-
tions dispensed on the day of the accident were excluded
because it could not be established whether, for the cases,
exposure occurred before or after the car crash.
New users were defined as subjects who used a driving
impairing medication in the week before the index date,
started their therapy up to 2 weeks before the index date,but
did not receive any prescriptions for this medication in the 6
months before the initiation of the therapy. Chronic users
were defined as subjects who used a driving impairing medi-
cation in the week before the index date and also used this
medication in the 6 months before the index date (Figure 1).
Monotherapy was defined as the use of only one study
medication and combination therapy was defined as the
concomitant use of at least two study medicines.
Statistical analysis
The statistical analysis was performed by using the statis-
tical package SPSS (SPSS 16.0 for Windows).
Descriptive statistics were used to examine both accid-
ent and demographic characteristics of cases and controls.
Logistic regression analysis was used to calculate the
odds ratios (ORs) of a traffic accident after exposure to the
study medications. The case–control status was used as a
dependent variable. The analysis compared the odds of
exposure to the study medications among the cases with
the odds of exposure among the controls. Exposure to one
of the study ATC groups (e.g. SSRIs) was compared with the
absence of exposure to the ATC groups of interest. Driver
and medication characteristic stratifications were perfor-
med (i.e. medication user type; gender, age and benzodiaz-
epine half-life) and adjusted ORs were computed (combina-
tion therapy adjustment).ORs were adjusted for psychotro-
pic drug polypharmacy because it is well known that the
concomitant use of medications can increase the risk of
adverse effects, medicine interactions and, consequently,
lead to an increased risk of traffic accidents [11, 14, 20].
95% confidence intervals (CIs) were calculated for all
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The study research protocol was reviewed by the
Medical Ethics Committee of the University Medical Centre
Groningen (UMCG), the Netherlands, which resulted in the
decision that, according the Dutch Medical Research
Involving Human Subjects Act (WOM), this case–control
study did not need an ethical approval.
Results
Data on 155 470 traffic accidents were available in the DVS
database whereas 64 937 licence numbers were associated
with a traffic accident in the RDW database during the
years 2000–2007. After the first phase of the linking
process, data on 90 533 traffic accidents were used in the
second phase of the linking process. After this second
phase, 3963 traffic accidents that satisfied the study inclu-
sion criteria were available.
With respect to the control selection, in the first phase
of the linking process, 6 916 598 driving licence holders
who did not have a traffic accident in the years 2000–2007
were selected from the RDW database. After the second
phase of the linking process, a database consisting of
858 039 subjects was available to perform the final control
selection. This led to the selection of 18 828 controls cor-
responding to the inclusion criteria.
Therefore, our final study population consisted of 3963
cases and 18 828 controls.
Eight-hundred and twenty-one cases were excluded
because they were either positive for alcohol (485 cases) or
had no data on alcohol use (336 cases).
Cases were mainly males (males = 62.5%) and they
mostly belonged to the age group 30–60 years (<30 years
= 28.7%, 30–60 years = 53.9%, >60 years = 17.4%).
Table 1 presents the accident characteristics of the
cases. From this table it can be seen that accidents were
equally distributed during the four seasons, they mainly
occurred on week days, with dry weather conditions, at
daylight, and between 13.00 h and 19.00 h. According to
the police report, the majority of the accidents were clas-
sified as either serious or moderately serious and, conse-
quently, the subjects were transported to the hospital to
receive further medical assistance.
Two-hundred and thirty-seven cases and 967 controls
were exposed to monotherapy of one of the study medi-
cations, and 76 cases and 236 controls were exposed to
combination therapy.
Table 2 shows in detail the medication exposure of
cases and controls. It can be seen that anxiolytics were the
most represented psychoactive medications, in both cases
and controls, followed by SSRIs, and hypnotics and sedatives.
Table 2 also presents the crude and adjusted ORs for
road traffic accidents related to psychoactive medication
use, stratified by user-type, gender and age.
A significant increased traffic accident risk was seen for
anxiolytics and SSRIs.
The data also illustrate that new users were associated
with a higher traffic accident risk compared with no use,
except for the SSRIs. However, this association was not sta-
tistically significant.
In relation to the gender stratifications, it can be seen
from Table 2 that there was a statistically significant
association between the risk of having a traffic accident
and female anxiolytic, and SSRI users. On the contrary, no
statistically significant association was found between
male users of the study medications and traffic accident
risk.
Lastly, analyses of medication exposure by age groups
indicated that only young anxiolytic and middle-aged SSRI
users were positively associated with a higher traffic acci-
dent risk.
Table 3 illustrates the crude and adjusted ORs for
road traffic accident in anxiolytic and hypnotic benzodi-
azepine users, stratified by half-life. As can be seen from
this table, a statistically significant association was only
found in the case of exposure to intermediate half-life
hypnotics.
Table 1
Accident characteristics (cases only)
Accident characteristics
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Discussion
The outcomes of this study showed that the use of psycho-
tropic medications could place drivers at a higher risk for a
traffic accident. In particular, the current study indicated
that there was a statistically significant association
between the risk of having a motor vehicle accident and
the exposure to axiolytics and SSRIs. The results of our
research also showed a significantly increased traffic acci-
dent risk in case of chronic SSRI users, intermediate half-life
hypnotic users, female anxiolytic and SSRI users and young
to middle-aged drivers (this latter association was statisti-
cally significant only for users of anxiolytics and SSRIs).
Contrary to expectations, our study revealed a signifi-
cant association between the risk of being involved in an
accident as a driver and the exposure to SSRIs (OR = 2.03,
95% CI = 1.31, 3.14). Although these findings differ from
previous studies which showed no increased risk of road-
traffic accidents in SSRI users [4, 5, 7, 8, 11, 27], they are in
line with those of Rapoport et al. and Hooper et al. who,
however, focused on very specific populations (i.e. patients
with dementia and military population, respectively) [28,
Table 2
Exposed subjects [cases (n = 3963) and controls (n = 18 828)], crude and adjusted ORs* for road-traffic accident in different psychotropic medicine group
users, stratified user type, gender, and age
Medicine group Cases (exposed) (%) Controls (exposed) (%) Crude ORs (95% CI) Adj. ORs (95% CI)
Antipsychotics
All exposed individuals 20 (0.50) 96 (0.51) 1.01 (0.62, 1.63) 1.31 (0.71,2.42)
New users 1 (0.03) 3 (0.02) 1.61 (0.17, 15.48) 1.61 (0.17, 15.48)
Chronic users 19 (0.48) 93 (0.49) 0.99 (0.60, 1.62) 1.29 (0.68, 2.44)
Males 12 (0.30) 63 (0.33) 0.92 (0.50, 1.71) 1.00 (0.41, 2.41)
Females 8 (0.20) 33 (0.18) 1.17 (0.54, 2.54) 1.78 (0.75, 4.24)
<30 years 3 (0.08) 19 (0.10) 0.76 (0.23, 2.58) 2.41 (0.60, 9.66)
30–60 years 15 (0.38) 63 (0.33) 1.15 (0.65, 2.02) 1.32 (0.63, 2.75)
>60 years 2 (0.05) 14 (0.07) 0.69 (0.16, 3.04) 0.54 (0.10, 4.24)
Anxiolytics
All exposed individuals 94 (2.37) 310 (1.65) 1.46 (1.16, 1.85) 1.54 (1.11, 2.15)
New users 15 (0.38) 41 (0.22) 1.77 (0.98, 3.20) 1.81 (0.71, 4.63)
Chronic users 79 (1.99) 269 (1.43) 1.41 (1.01, 1.83) 1.51 (1.06, 2.16)
Males 49 (1.24) 162 (0.86) 1.46 (1.06, 2.01) 1.22 (0.74, 2.03)
Females 45 (1.14) 148 (0.79) 1.47 (1.05, 2.05) 1.89 (1.21, 2.95)
<30 years 8 (0.20) 19 (0.10) 2.03 (0.89, 4.65) 4.02 (1.23, 13.19)
30–60 years 58 (1.46) 185 (0.98) 1.51 (1.12, 2.04) 1.51 (1.00, 2.28)
>60 years 28 (0.71) 106 (0.56) 1.28 (0.84, 1.94) 1.27 (0.65, 2.46)
Hypnotics and sedatives
All exposed individuals 76 (1.92) 273 (1.45) 1.34 (1.04, 1.74) 1.39 (0.94, 2.07)
New users 6 (0.15) 21 (0.11) 1.38 (0.56, 3.42) 2.76 (0.81, 9.43)
Chronic users 70 (1.77) 252 (1.34) 1.34 (1.03, 1.75) 1.30 (0.86, 1.98)
Males 33 (0.83) 142 (0.75) 1.12 (0.77, 1.64) 1.21 (0.64, 2.28)
Females 43 (1.09) 131 (0.70) 1.59 (1.12, 2.24) 1.53 (0.93, 2.54)
<30 years 2 (0.05) 11 (0.06) 0.88 (0.2, 3.96) 0.97 (0.11, 8.27)
30–60 years 33 (0.83) 123 (0.65) 1.30 (0.88, 1.91) 1.40 (0.83, 2.37)
>60 years 41 (1.03) 139 (0.74) 1.42 (1.00, 2.02) 1.43 (0.77, 2.65)
SSRIs
All exposed individuals 92 (2.32) 252 (1.34) 1.76 (1.38, 2.24) 2.03 (1.31, 3.14)
New users 7 (0.18) 16 (0.08) 2.11 (0.87, 5.14) 1.81 (0.48, 6.83)
Chronic users 85 (2.14) 236 (1.25) 1.74 (1.35, 2.23) 2.06 (1.30, 3.26)
Males 40 (1.01) 122 (0.65) 1.58 (1.11, 2.27) 1.46 (0.72, 2.97)
Females 52 (1.31) 130 (0.69) 1.93 (1.40, 2.67) 2.55 (1.46, 4.45)
<30 years 16 (0.40) 30 (0.16) 2.58 (1.40, 4.73) 3.02 (0.99, 9.23)
30–60 years 57 (1.44) 183 (0.97) 1.50 (1.12, 2.03) 1.74 (1.01, 2.98)
>60 years 19 (0.48) 39 (0.21) 2.35 (1.36, 4.08) 2.63 (0.97, 7.13)
Other antidepressants
All exposed individuals 40 (1.01) 146 (0.78) 1.32 (0.93, 1.88) 1.45 (0.81, 2.58)
New users 3 (0.08) 7 (0.04) 2.07 (0.54, 8.00) 2.41 (0.22, 26.63)
Chronic users 37 (0.93) 139 (0.74) 1.29 (0.89, 1.85) 1.41 (0.78, 2.56)
Males 16 (0.40) 66 (0.35) 1.17 (0.68, 2.02) 1.61 (0.72, 3.59)
Females 24 (0.61) 80 (0.42) 1.45 (0.92, 2.29) 1.30 (0.56, 3.00)
<30 years 2 (0.05) 13 (0.07) 0.74 (0.17, 3.29) 4.83 (0.32, 77.21)
30–60 years 28 (0.71) 95 (0.50) 1.42 (0.93, 2.17) 1.48 (0.75, 2.90)
>60 years 10 (0.25) 38 (0.20) 1.27 (0.63, 2.55) 1.11 (0.32, 3.91)
*ORs adjusted for combination therapy. Bold = Statistically significant.
Medicines and traffic accidents: a case–control study in the Netherlands
Br J Clin Pharmacol / 72:3 / 509
29]. Our results are also consistent with those of Orriols
et al. who, however, did not specifically focus on SSRIs but
on psychoanaleptics as a total group [10]. A possible expla-
nation for our SSRI findings might be that a proportion of
reported car accidents could have been intentional, and,
therefore, associated with the risk of suicide in relation to
antidepressant use [30, 31] or with not properly diagnosed
or treated depression which is well-known to play a causal
role in suicidal deaths [32–34]. These results may also be
explained by the fact that depression itself can affect
driving abilities and driving related skills by causing, for
example, confusion, poor concentration, and cognitive
impairment [28, 35–37]. These outcomes may also be due
to comorbid psychiatric conditions and coexisting medical
illnesses, which often occur in conjunction with depression
and can influence the ability to drive, as well [38]. Another
possible explanation is that the side effects of a single SSRI
could have accounted for the increased ORs of SSRIs [8]
or it is also possible that these results are due to lack
of therapy adherence which has been often seen in
depressed patients and might result in more severe
adverse drug events and treatment failure [39, 40]. Lastly,
the observed increase in traffic accident risk could also be
related to the fact that, generally speaking, SSRIs are con-
sidered to be unlikely to produce driving performance
impairment and, therefore, patients continue to drive
during their course of treatment, exposing themselves to a
greater risk of being involved in a traffic accident.
Surprisingly, our study did not find a strong association
between road-traffic accidents and anxiolytics, and hyp-
notics and sedatives (anxiolytics: OR = 1.54, 95% CI 1.11,
2.15; hypnotics and sedatives: OR = 1.39, 95% CI 0.94, 2.07,
not statistically significant), which are both well-known
driving impairing medication groups [4, 5, 7, 8, 11–13]. It is
difficult to explain these results, but they could be related
to the fact that these medicines can be often taken at
subtherapeutic doses for different indications (anxiolytics)
[41] or at night (hypnotics) [12], and expose their users to a
lower impairment and, therefore, a decreased likelihood of
experiencing a car crash. Another possible explanation for
our findings could be that anxiolytic and hypnotic and
sedative users, following the advice of their health care
providers, tend not to drive, and, consequently, could be
less exposed to a motor vehicle collision risk [42].
With regard to the user type, our research showed that
the risk associated with psychotropic medication users
was the highest among new users, even though this asso-
ciation was not found to be statistically significant in any of
the selected medication groups. On the contrary, our
results showed a significant increased risk in chronic SSRI
users (OR = 2.06, 95% CI 1.30, 3.26). Very little was found
in the literature on these latter findings. Nevertheless,
the observed increased risk in chronic users of SSRIs
could be explained by residual depressive symptoms [27,
43] or it could be attributed to a not fully achieved clinical
remission by antidepressant treatment.
On the question of medicine half-life, the current study
found a strong association between the exposure to inter-
mediate half-life hypnotics and traffic accident risk (OR =
6.44, 95% CI 1.44, 28.78), and a positive, but not statistically
significant, association in case of long half-life anxiolytic
exposure (OR = 1.57, 95% CI 0.82, 3.01). These ORs confirm
previous research [7, 8, 12, 44–47] and might be due to the
fact that benzodiazepines with an intermediate/long half-
life might have a longer duration of action or might accu-
mulate and cause excessive sedation, and, consequently,
have an extended negative effect on driving performance
[8, 44, 45, 48].
The current study also indicated that female patients
were more often significantly associated with the risk of
having a traffic accident than male patients.These findings
do not support previously published studies which
showed an increased accident risk in male patients [29, 46,
47, 49]. It is difficult to explain these outcomes, but they
could be related to biological differences between females
and males which might expose women to a greater risk of
developing adverse medicine reactions than men [44, 50,
51]. Lastly, it is interesting to note that, according to our
descriptive statistics, males were more often involved in a
car crash than females.This rather contradictory result may
be attributed to the fact that, on average, men drive more
miles than women [52, 53] or to the higher propensity of
Table 3
Crude and adjusted ORs* for road-traffic accidents in anxiolytic and hypnotic benzodiazepine users, stratified by half-life
Medicine group Cases (exposed) (%) Controls (exposed) (%) Crude ORs (95% CI) Adj. ORs (95% CI)
Anxiolytic benzodiazepines
Short half-life 0 0 – –
Intermediate half-life 42 (1.06) 222 (1.18) 0.91 (0.66, 1.27) 1.13 (0.73, 1.75)
Long half-life 26 (0.66) 84 (0.45) 1.50 (0.96, 2.32) 1.57 (0.82, 3.01)
Hypnotic benzodiazepines
Short half-life 20 (0.50) 128 (0.68) 0.75 (0.47, 1.21) 0.79 (0.39, 1.60)
Intermediate half-life 6 (0.15) 4 (0.02) 7.24 (2.04, 25.68) 6.44 (1.44, 28.78)
Long half-life 31 (0.78) 138 (0.73) 1.10 (0.73, 1.60) 1.42 (0.80, 2.53)
*ORs adjusted for combination therapy. Bold = Statistically significant.
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male drivers to engage in aggressive and risky behavi-
our [54] or to the proneness of female drivers to adjust
their driving behaviour when using a driving impairing
medication [55].
In reference to the age stratifications, we found that,
generally speaking, the use of psychotropic medicines by
young and middle-aged patients could account for a
higher risk of motor vehicle crashes. It is possible that these
results can be related either to the higher number of miles
driven by the younger population (given that this popula-
tion represents the working population) [52, 56] or to the
fact that young/middle-aged subjects tend to use these
medications intermittently or to start driving earlier while
still being exposed to driving impairing medications, and,
therefore, without having developed tolerance to these
medicines [12, 57]. These findings are in agreement with
earlier findings [12, 13, 46, 47, 49, 55] and are also reflected
in the descriptive statistics of our study.
To conclude, a number of limitations need to be con-
sidered. First, a pharmacy dispensing database was used
for our study. The fact that the prescribed medications
were dispensed does not imply that the patient actually
took these medications or used them according to the
prescription or to the information that was stored in the
PHARMO database. Second, both cases and controls
mainly used their medications either on a low or regular
dosage. Therefore, it was not possible to examine the role
of high medication dosage which is also known to be
related to an increased risk of road-traffic accidents [12,
44, 58]. Third, there was no possibility to obtain informa-
tion on medications prescribed during recent hospitaliza-
tion or the concomitant use of over the counter
medicines which could also have played a role in endan-
gering traffic safety. Fourth, no information was available
on what medical condition the psychotropic medications
were prescribed for or on patients’ comorbidities which
both might have biased our outcomes [5, 13, 47]. Fifth, it
was assumed that cases and controls regularly drove a car.
This was a rough assumption, based on that fact that both
cases and controls had a driving licence, but there was no
other possibility to gain better insight into the driving
patterns of our study population. Sixth, it was not possible
to assess other influential factors, such as number of miles
driven, risk taking behaviour (e.g. illicit drug use among
cases and controls, alcohol use among controls, speeding,
etc.), driving conditions, driving patterns associated with
periods of use and non-use of a medication, driving expe-
rience and skills, which can also play a role in endangering
traffic safety [29]. Finally, the database linkage process led
to a considerable loss of cases. This sometimes resulted in
small numbers which did not allow proper stratified
analyses and thus fully reliable outcomes (e.g. user type
and age stratifications).
Despite of these limitations, it is important to underline
that, to our knowledge, this matched case–control study is
one of the first studies to examine the risk of having a
traffic accident associated with exposure to a large and
comprehensive set of different driving impairing medica-
tions and to investigate the role of other influential predic-
tors such as user type, gender, age and medication half-life.
Furthermore, it is noteworthy to point out that our study
used the data from a large and representative population,
it combined different and reliable data sources, and it also
focused on a broad time frame.
In conclusion, the results of this study confirmed previ-
ous findings and those of a recent French study [10] on
prescription medicines and road traffic crash risk and con-
tributed additional evidence that psychotropic medica-
tions can constitute a considerable danger for traffic safety,
especially for patients with no medicine use experience,
female, and young psychoactive medication users.The evi-
dence from this study suggests that, on the one hand,
drivers should be aware of the risk of accident involvement
associated with different treatment conditions and receive
proper counselling from their health care providers, and,
on the other hand, physicians and pharmacists should be
able to minimize the risk of patients causing traffic acci-
dents while driving under the influence of psychotropic
medications by providing accurate advice, choosing safer
alternatives, monitoring their patients’ driving experience
with the medication, and, if needed, advising them not to
drive until they are fit to drive.
It is recommended that more research should be
undertaken to investigate further the effect of SSRIs in
traffic accidents in order to understand better the extent
to which these antidepressants can cause or contribute
to accidents. Moreover, more work needs to be done to
determine the role of medication dose and dose changes,
non-psychoactive medicines, and medical conditions.
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